Below you will find relevant news links and information:

MDCSCO Fall 2009 Newsletter (pdf)

Past Newsletter Issues:

MDCSCO Winter 2008 Newsletter (pdf)

Novartis Pharmaceuticals Corporation Announces Afinitor tablets
Novartis Pharmaceuticals Corporation is pleased to announce the introduction of Afinitor® (everolimus) tablets, approved by the FDA on March 30, 2009. Afinitor® is a once daily oral mTOR inhibitor indicated for the treatment of advanced Renal Cell Carcinoma (RCC). Afinitor® is available by prescription only and package in a blister card. Click here for more information.

Velcade- Highlights of Prescribing Information

Velcade Physician Announcement Letter

Velcade Press Release
FDA APPROVES ADDITION OF SUSTAINED OVERALL SURVIVAL BENEFIT TO LABEL FOR VELCADE^® (BORTEZOMIB) FOR INJECTION FOR PATIENTS WITH PREVIOUSLY UNTREATED MULTIPLE MYELOMA